Actively Recruiting
Study of Angiotensin-1-7 and Related Factors in Children Ages 7 to 18 with New Hypertension or Normal Blood Pressure Examining Heart and Kidney Effects and Treatment Responses
Led by Wake Forest University Health Sciences · Updated on 2025-12-11
125
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
W
Wake Forest University Health Sciences
Lead Sponsor
N
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research aims to understand how specific components of the renin-angiotensin-aldosterone system, uric acid, and klotho contribute to high blood pressure and related damage in children and adolescents aged 7 to 18 years. It compares children newly diagnosed with primary hypertension to healthy controls, investigating how these biological factors affect the heart, kidneys, blood vessels, and brain over time. The study focuses on the variability in disease traits and treatment responses using detailed biological and clinical measurements. Participants are divided into two groups children with newly diagnosed primary hypertension and healthy children with normal blood pressure. Blood and urine samples are collected to analyze levels of various substances such as Ang-1-7, ACE2, and uric acid. Blood pressure, heart function and structure, kidney function, autonomic nervous system function, and vascular function are measured at the start, after one year for both groups, and after two years for the hypertension group, allowing researchers to observe changes over time and responses to treatment. Throughout the study, participants undergo multiple assessments including blood and urine tests, blood pressure monitoring, echocardiograms, and measurements of autonomic and vascular function. These evaluations occur at baseline, one year, and two years to track health changes and treatment effects. The study also monitors changes in biomarkers and organ function to better understand hypertensions impact and guide future patient care. Participants and their caregivers are expected to commit to completing all assessments during the study period.
CONDITIONS
Brief Title
Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 7 and 18 years at enrollment
- New diagnosis of primary hypertension with no identifiable secondary cause for Hypertension Cohort
- For Hypertension Cohort: Blood pressure at or above 95th percentile or 130/80 mmHg (age under 13) or at or above 130/80 mmHg (age 13 or older)
- For Control Cohort: Normal blood pressure below 90th percentile or 120/80 mmHg (age under 13) or below 120/80 mmHg (age 13 or older)
- Participants and caregivers willing and able to complete all study assessments
You will not qualify if you...
- Younger than 7 or older than 18 years at enrollment
- For Hypertension Cohort: Blood pressure confirmed as normal or elevated but below hypertension threshold based on multiple measurements
- For Control Cohort: Elevated blood pressure or history of hypertension
- Confirmed secondary cause of hypertension
- Other heart or kidney diseases, vascular or inflammatory diseases, or diabetes (except hypertension-related heart changes or albuminuria)
- Inability to complete study assessments
- Non-English or non-Spanish speakers
- Current pregnancy
- Ward of the State
Research Team
A
Andrew M South, MD, MS
C
Caroline B Lucas
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here